About Centocor

The Centocor legacy began more than a quarter century ago with a single vision: to improve patients' lives by pioneering new technologies aimed at developing therapies for immune-related diseases. That vision came to fruition in 1998 when Centocor received its first U.S. Food and Drug Administration approval for such a biologic agent. Since that milestone approval, Centocor has strived to bring corporate responsibility to a new level by not only developing breakthrough therapies, but also, by creating programs that further communicate the company's commitment to patients.

Centocor builds on the company's roster of "firsts" with the launch of INNERSTATE, a first-of-its-kind documentary chronicling the lives of three adults diagnosed with chronic diseases of the immune system. The INNERSTATE program breaks down the wall between traditional patient awareness efforts and the unvarnished realities of coping with a devastating disease.

The world leader in monoclonal antibody production and technology, Centocor remains committed to its original vision. With more than 250 scientists dedicated to clinical research worldwide and 13 compounds in early- or late-stage development, the company's ambitious pipeline holds the promise of continued innovative biomedicines well into the future. Through the science of biologics — which involves cultivating and growing proteins from living cells — Centocor has created revolutionary therapies for the treatment of people living with gastroenterologic, rheumatologic, and dermatologic diseases.

For more information about Centocor, visit the company's website at www.centocor.com.